Mucinex Childrens Stuffy Nose

Description

Mucinex® Children's Stuffy Nose Spray is a nasal decongestant formulated with oxymetazoline hydrochloride at a concentration of 0.05%. This product is designed to provide fast relief from nasal congestion for children aged 6 years and older. Each bottle contains 3/4 fluid ounce (22 mL) of the solution, which is intended for use as a nasal spray. The product is effective for up to 12 hours, offering prolonged relief from a stuffy nose. The National Drug Code (NDC) for this formulation is 63824-961-22.

Uses and Indications

This drug is indicated for the temporary relief of nasal congestion associated with a cold, hay fever, or other upper respiratory allergies. It promotes nasal and sinus drainage, providing temporary relief from sinus congestion and pressure. Additionally, this drug aids in clearing nasal passages by shrinking swollen membranes.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Adults and children aged 6 to under 12 years of age, under adult supervision, are advised to administer 2 or 3 sprays in each nostril. Dosing should not occur more frequently than every 10 to 12 hours, and it is important not to exceed 2 doses within a 24-hour period. For children under 6 years of age, consultation with a healthcare professional is recommended prior to use.

Prior to administration, the bottle should be shaken well. To open the bottle, hold it by the white grips, then squeeze and turn the cap. Before the initial use, the protective cap from the tip must be removed, and the metered pump should be primed by firmly depressing it several times.

For the actual spraying technique, the bottle should be held with the thumb at the base and the nozzle positioned between the first and second fingers. The nozzle should be inserted into the nostril without tilting the head. The pump must be fully depressed with a firm, even stroke while the patient sniffs deeply. After use, the nozzle should be wiped clean.

To close the bottle, turn the cap until it clicks securely into place.

Contraindications

The product should not be used in the following situations:

• Exceeding the recommended dosage is contraindicated due to the potential for adverse effects.

• Use of this product for more than 3 days is contraindicated to prevent the risk of complications associated with prolonged use.

Warnings and Precautions

Healthcare professionals should exercise caution when recommending this product. Prior to use, it is imperative to consult a physician if the patient or child has any of the following conditions: heart disease, high blood pressure, thyroid disease, diabetes, or difficulty in urination due to prostate gland enlargement.

It is essential to adhere strictly to the recommended dosage guidelines. The product should not be used for more than three consecutive days, and it must be utilized only as directed. Prolonged or frequent use may lead to a recurrence or worsening of nasal congestion. Patients may experience temporary discomfort, including burning, stinging, sneezing, or an increase in nasal discharge. Additionally, sharing this product among multiple users may pose a risk of infection transmission.

Patients should be advised to discontinue use and consult a physician if symptoms persist. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Side Effects

Patients using this product may experience temporary discomfort, which can include burning, stinging, sneezing, or an increase in nasal discharge. It is important to note that frequent or prolonged use of the product may lead to a recurrence or worsening of nasal congestion.

Patients are advised to discontinue use and consult a healthcare professional if symptoms persist. Additionally, the use of this container by more than one person may pose a risk of spreading infection. In the event of accidental ingestion, it is crucial to seek medical assistance or contact a Poison Control Center immediately.

Drug Interactions

There are no specific drug interactions or laboratory test interactions identified in the available data. Therefore, no dosage adjustments or monitoring recommendations are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Mucinex Childrens Stuffy Nose (oxymetazoline hydrochloride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 6 years of age should consult a doctor prior to use. For children aged 6 to under 12 years, the recommended dosage is 2 or 3 sprays in each nostril, administered no more frequently than every 10 to 12 hours. It is important not to exceed 2 doses within a 24-hour period. Adult supervision is advised for this age group during administration.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, as the prescribing information does not provide any age considerations, dosage adjustments, or safety concerns pertinent to this population. Consequently, healthcare providers should exercise clinical judgment when prescribing this medication to geriatric patients, as individual patient factors may influence treatment outcomes. Monitoring for efficacy and safety is advised, given the absence of tailored recommendations for elderly patients.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. It is important to assess the potential risks and benefits associated with the use of this drug during pregnancy and lactation. Healthcare providers can offer guidance based on individual circumstances and the latest clinical data.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to this drug. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population.

Overdosage

In the event of an overdosage, it is imperative to keep the product out of reach of children. Should ingestion occur, immediate medical assistance is required. Healthcare professionals are advised to contact a Poison Control Center without delay to ensure appropriate management and intervention.

Prompt action is crucial in mitigating potential adverse effects associated with overdosage. The symptoms may vary depending on the specific substance involved; therefore, a thorough assessment and appropriate treatment plan should be initiated based on the clinical presentation and guidance from poison control experts.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question. Further studies may be necessary to elucidate these aspects of nonclinical toxicology.

Postmarketing Experience

Postmarketing experience has indicated that side effects may be reported voluntarily through designated channels. Healthcare professionals and patients are encouraged to communicate any adverse events encountered during the use of the product. This information contributes to ongoing safety monitoring and the overall understanding of the product's risk profile.

Patient Counseling

Healthcare providers should advise patients to keep this product out of reach of children. Instruct patients that if the product is swallowed, they should seek medical help or contact a Poison Control Center immediately.

Patients should be informed to stop using the product and consult a doctor if symptoms persist. It is important to emphasize that while using this product, patients must not exceed the recommended dosage and should not use it for more than three days. They should use the product only as directed, as frequent or prolonged use may lead to a recurrence or worsening of nasal congestion.

Patients may experience temporary discomfort while using the product, which can include burning, stinging, sneezing, or an increase in nasal discharge. Additionally, inform patients that the use of this container by more than one person may increase the risk of spreading infection.

Healthcare providers should also recommend that patients consult a doctor before using the product if they or their child have any of the following conditions: heart disease, high blood pressure, thyroid disease, diabetes, or difficulty in urination due to enlargement of the prostate gland.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at a controlled temperature range of 20-25°C (68-77°F) to maintain its integrity and efficacy. Proper storage conditions must be adhered to, ensuring that the product is kept within the specified temperature limits to prevent degradation.

Additional Clinical Information

The medication is administered via the nasal route. For adults and children aged 6 to under 12 years, the recommended dosage is 2 or 3 sprays in each nostril, with a frequency not exceeding every 10 to 12 hours, and a maximum of 2 doses within a 24-hour period. For children under 6 years of age, consultation with a doctor is advised prior to administration.

There is no additional information available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Mucinex Childrens Stuffy Nose, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)